RIPK2

Across TCGA pan-cancer cohorts, RIPK2 mass-spec protein differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of RIPK2’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where RIPK2 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types RIPK2 is over-expressed in tumor, although a few such as LSCC show the opposite, repressed pattern.

CCRCC, COAD, and HNSC are the cancer types where RIPK2 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in RIPK2 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	Female	II,III,IV	+0.721	<.001	12	view →
COAD	Male	III,IV	+0.627	<.001	11	view →
HNSC	Male	IV	+0.287	<.001	8	view →
PDAC	Male	All	+0.468	<.001	7	view →
LSCC	Male	III,IV	−0.177	.002	6	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

RIPK2–CCRCC

Open the CCRCC breakdown →